At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 12 enrolled
Drug / intervention
CP-690,550drug
Likely dose
CP-690,550 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1, Open-Label Study Of The Pharmacokinetics, Non-Renal Clearance And Dialyzability Of CP-690,550 In Subjects With End-Stage Renal Disease Undergoing Hemodialysis
In Brief
A Phase 1 clinical trial evaluating CP-690,550 for End-Stage Renal Disease and Hemodialysis. Completed, enrolled 12 participants across 2 sites.
Detailed Summary
There were 2 study periods in this study. In the Period 1, CP-690,550 was to be administered approximately 1 to 2 hours following hemodialysis. If significant non-renal clearance of the drug occurred such that dialyzability of CP-690,550 could not be assessed in Period 1, a second period (Period 2) will be conducted. In Period 2, a single dose of drug will be administered approximately 4 hours prior to hemodialysis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEnd-Stage Renal Disease, Hemodialysis
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2003
Primary CompletionJun 2003
First PostedOct 2012
TodayJul 2026
First PostedOct 18, 2012
Enrollment StartFeb 1, 2003
Primary CompletionJun 1, 2003
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 13.7 years ago
Interventions
CP-690,550drug
CP-690,550 10 mg oral powder for constitution